The technique, called hyperpolarised carbon-13 imaging, can increase the detected signal in an MRI scanner by more than 10,000 times. Scientists have found that the technique can distinguish between two different subtypes of ovarian cancer, to reveal their sensitivities to treatment.
They used it to look at patient-derived cell models that closely mimic the behaviour of human high grade serous ovarian cancer, the most common lethal form of the disease. The technique clearly shows whether a tumour is sensitive or resistant to Carboplatin, one of the standard first-line chemotherapy treatments for ovarian cancer.
This will enable oncologists to predict how well a patient will respond to treatment, and to see how well the treatment is working within the first 48 hours.
Professor Kevin Brindle, stated: “We can image a tumour pre-treatment to predict how likely it is to respond, and then we can image again immediately after treatment to confirm whether it has indeed responded. This will help doctors to select the most appropriate treatment for each patient and adjust this as necessary.”
This study adds to the evidence for the value of the hyperpolarised carbon-13 imaging technique for wider clinical use.
